Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings

Multiple Sclerosis

Volumn 20, Issue 1, 2014, Pages 27-34

  Virtanen, J O ^a   Wohler, J ^a   Fenton, K ^a   Reich, D S ^a   Jacobson, S ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

immunology; magnetic resonance imaging; Multiple sclerosis

Indexed keywords

OLIGOCLONAL BAND; VIRUS DNA; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN HERPESVIRUS 6; ISOELECTRIC FOCUSING; MALE; MULTIPLE SCLEROSIS; NEPHELOMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID LEVEL; CORRELATIONAL STUDY; DNA DETERMINATION; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MIDDLE AGED; NONHUMAN; PREVALENCE; YOUNG ADULT;

IMMUNOLOGY; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

ADULT; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HERPESVIRUS 6, HUMAN; HUMANS; IMMUNOBLOTTING; ISOELECTRIC FOCUSING; LUMINESCENT MEASUREMENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; POLYMERASE CHAIN REACTION; ROSEOLOVIRUS INFECTIONS; YOUNG ADULT;

EID: 84890842607     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513490545     Document Type: Article

References (36)

1. Handel AE, Giovannoni G, Ebers GC, et al. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol. 2010 ; 6: 156-166
2. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 ; 69: 292-302
3. Derfuss T, Gurkov R, Then Bergh F, et al. Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain. 2001 ; 124: 1325-1335
4. Fainardi E, Castellazzi M, Tamborino C, et al. Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms. J Neurovirol. 2009 ; 15: 425-433
5. Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest. 2005 ; 115: 1352-1360
6. Franciotta D, Di Stefano AL, Jarius S, et al. Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. J Neuroimmunol. 2011 ; 230: 160-163
7. Virtanen JO, Pietilainen-Nicklen J, Uotila L, et al. Intrathecal human herpesvirus 6 antibodies in multiple sclerosis and other demyelinating diseases presenting as oligoclonal bands in cerebrospinal fluid. J Neuroimmunol. 2011 ; 237: 93-97
8. Yao K, Honarmand S, Espinosa A, et al. Detection of human herpesvirus-6 in cerebrospinal fluid of patients with encephalitis. Ann Neurol. 2009 ; 65: 257-267
9. Villegas E, Santiago O, Carrillo JA, et al. Low intrathecal immune response of anti-EBNA-1 antibodies and EBV DNA from multiple sclerosis patients. Diagn Microbiol Infect Dis. 2011 ; 70: 85-90
10. Simon JH, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol. 2006 ; 27: 455-461
11. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: A consensus statement. Arch Neurol. 2005 ; 62: 865-870
12. Olsson JE, Link H. Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions. Arch Neurol. 1973 ; 28: 392-399
13. Alvarez-Lafuente R, Garcia-Montojo M, De Las Heras V, et al. Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients. Mult Scler. 2008 ; 14: 595-601
14. Challoner PB, Smith KT, Parker JD, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A. 1995 ; 92: 7440-7444
15. Cermelli C, Berti R, Soldan SS, et al. High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis. 2003 ; 187: 1377-1387
16. Virtanen JO, Zabriskie JB, Siren V, et al. Co-localization of human herpes virus 6 and tissue plasminogen activator in multiple sclerosis brain tissue. Med Sci Monit. 2005 ; 11: BR84 - BR87
17. Goodman AD, Mock DJ, Powers JM, et al. Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions. J Infect Dis. 2003 ; 187: 1365-1376
18. Tuke PW, Hawke S, Griffiths PD, et al. Distribution and quantification of human herpesvirus 6 in multiple sclerosis and control brains. Mult Scler. 2004 ; 10: 355-359
19. Alvarez-Lafuente R, De Las Heras V, Bartolome M, et al. Human herpesvirus 6 and multiple sclerosis: A one-year follow-up study. Brain Pathol. 2006 ; 16: 20-27
20. Derfuss T, Hohlfeld R, Meinl E. Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. J Neurol. 2005 ; 252: 968-971
21. Virtanen JO, Farkkila M, Multanen J, et al. Evidence for human herpesvirus 6 variant A antibodies in multiple sclerosis: Diagnostic and therapeutic implications. J Neurovirol. 2007 ; 13: 347-352
22. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: A prospective study. JAMA. 2001 ; 286: 3083-3088
23. Handel AE, Williamson AJ, Disanto G, et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One. 2010 ; 5: e12496
24. Willis SN, Stadelmann C, Rodig SJ, et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009 ; 132: 3318-3328
25. Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007 ; 204: 2899-2912
26. Pohl D, Rostasy K, Jacobi C, et al. Intrathecal antibody production against Epstein-Barr and other neurotropic viruses in pediatric and adult onset multiple sclerosis. J Neurol. 2010 ; 257: 212-216
27. Jaquiery E, Jilek S, Schluep M, et al. Intrathecal immune responses to EBV in early MS. Eur J Immunol. 2010 ; 40: 878-887
28. Jafari N, van Nierop GP, Verjans GM, et al. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis. J Clin Virol. 2010 ; 49: 26-31
29. Sargsyan SA, Shearer AJ, Ritchie AM, et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology. 2010 ; 74: 1127-1135
30. Rostrom B, Link H, Laurenzi MA, et al. Viral antibody activity of oligoclonal and polyclonal immunoglobulins synthesized within the central nervous system in multiple sclerosis. Ann Neurol. 1981 ; 9: 569-574
31. Peferoen LA, Lamers F, Lodder LN, et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain. 2010 ; 133: e137
32. Owens GP, Bennett JL. Trigger, pathogen, or bystander: The complex nexus linking Epstein-Barr virus and multiple sclerosis. Mult Scler. 2012 ; 18: 1204-1208
33. Petereit HF, Reske D. Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients - follow-up and clinical implications. Cerebrospinal Fluid Res. 2005 ; 2: 3
34. Reddehase MJ, Mutter W, Munch K, et al. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol. 1987 ; 61: 3102-3108
35. Jonjic S, Pavic I, Polic B, et al. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med. 1994 ; 179: 1713-1717
36. Kim IJ, Flano E, Woodland DL, et al. Antibody-mediated control of persistent gamma-herpesvirus infection. J Immunol. 2002 ; 168: 3958-3964